VEGF-C–induced lymphangiogenesis potentiated adoptive T-cell therapy in a heterotopic B16 melanoma model and anti-PD-1 therapy in a transgenic BrafV600E/Pten−/− melanoma mouse model in one study [97]. Here, VEGFC is linked to melanoma.